Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Elevation Pharma Secures US$17 Million In Second Tranche Of Series A Financing 16
Private Equity 18
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 18
Partnerships 19
ex scientia Enters into Research Agreement with Sunovion Pharma 19
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 20
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 21
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 22
Licensing Agreements 23
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 23
Sunovion Pharma Enters into Licensing Agreement with Novartis 24
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 25
Equity Offering 26
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 26
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 28
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 30
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 33
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 34
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 35
Cynapsus Therapeutics Postpones Private Placement Of US$10.5 Million 36
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.29 Million 37
Debt Offering 38
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 38
Cynapsus Therapeutics Completes Public Offering Of Secured Series D Debentures For US$0.51 Million 40
Cynapsus Therapeutics Completes Public Offering Of Secured Series C Debentures For US$0.3 Million 41
Asset Transactions 42
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 42
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 43
Acquisition 44
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 44
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 46
Cynapsus Therapeutics Completes Acquisition Of Adagio Pharma 48
Sunovion Pharmaceuticals Inc – Key Competitors 49
Sunovion Pharmaceuticals Inc – Key Employees 50
Sunovion Pharmaceuticals Inc – Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Recent Developments 52
Product News 52
10/13/2016: Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow for the Treatment of Patients with Chronic Obstructive Pulmonary Disease 52
06/21/2016: Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders 54
05/30/2016: Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting 56
04/04/2016: PsychoGenics Drug Discovery Collaboration with Sunovion Achieves a Milestone 57
Product Approvals 58
Jun 30, 2017: Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for SUN-101/eFlow (glycopyrrolate) for the Treatment of Chronic Obstructive Pulmonary Disease 58
Jun 12, 2017: PsychoGenics Achieves a Milestone in Drug Discovery Collaboration with Sunovion 59
May 26, 2017: Sunovion Receives Complete Response Letter from FDA for SUN-101/eFlow (glycopyrrolate) New Drug Application for Chronic Obstructive Pulmonary Disease 60
Jul 29, 2016: Sunovion Submits New Drug Application for SUN-101/eFlow to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease 61
Clinical Trials 62
May 23, 2017: Sunovion Presents Phase 3 Data Showing Safety, Efficacy and Improvement in Quality of Life Outcomes in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease Treated with SUN-101/eFlow (glycopyrrolate) 62
Aug 29, 2016: Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 64
Aug 15, 2016: Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration 65
Aug 12, 2016: Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 66
Jul 22, 2016: Sunovion Announces Results of Phase 3 Long-Term Safety Study Showing SUN-101/eFlow (glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 67
Jul 18, 2016: Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 69
Jul 18, 2016: Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 71
Jun 07, 2016: PARI Pharma’s Investigational Closed eFlow Nebulizer System Used in Two Successful Phase 3 Clinical Studies Evaluating Sunovion’s SUN-101 (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease 72
Apr 27, 2016: Sunovion Pharmaceuticals Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease 73
Apr 15, 2016: Cynapsus Therapeutics Announces Data Presentations at the American Academy of Neurology Annual Meeting 75
Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline 76
Jan 07, 2016: Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinson’s Clinical Study 77
Other Significant Developments 79
Dec 15, 2016: Sunovion Announces Collaboration with AMDA – The Society for Post-Acute and Long-Term Care Medicine 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Sunovion Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Elevation Pharma Secures US$17 Million In Second Tranche Of Series A Financing 16
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 18
ex scientia Enters into Research Agreement with Sunovion Pharma 19
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 20
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 21
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 22
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 23
Sunovion Pharma Enters into Licensing Agreement with Novartis 24
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 25
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 26
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 28
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 30
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 33
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 34
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 35
Cynapsus Therapeutics Postpones Private Placement Of US$10.5 Million 36
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.29 Million 37
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 38
Cynapsus Therapeutics Completes Public Offering Of Secured Series D Debentures For US$0.51 Million 40
Cynapsus Therapeutics Completes Public Offering Of Secured Series C Debentures For US$0.3 Million 41
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 42
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 43
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 44
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 46
Cynapsus Therapeutics Completes Acquisition Of Adagio Pharma 48
Sunovion Pharmaceuticals Inc, Key Competitors 49
Sunovion Pharmaceuticals Inc, Key Employees 50
Sunovion Pharmaceuticals Inc, Other Locations 51
Sunovion Pharmaceuticals Inc, Subsidiaries 51